title: [Response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia].
abstract: BACKGROUND
  Chronic myeloid leukemia represents 15 % of all the leukemias in adults. With the introduction of tyrosine kinase inhibitors, overall survival at 10 years is 80-90 %. The objective was to describe the epidemiology, complete cytogenetic response and major molecular response with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
  
  
  METHODS
  It was performed a descriptive cross-sectional study of patients with chronic myeloid leukemia and Philadelphia chromosome-positive in treatment with tyrosine kinase inhibitors.
  
  
  RESULTS
  The sample included 54 patients with a mean age of 41 years; 78 % of patients were in chronic phase, and in 8 % of patients were identified complex karyotype at diagnosis. All patients received imatinib as first-line treatment. We identified mutations in 8 %. The patients with primary or secondary resistance (30%) received second-generation tyrosine kinase inhibitors as a second-line therapy. Of 35 patients treated with imatinib, 23 had complete cytogenetic response, 23 had major molecular response, and 16 had loss of response to treatment. Of nine patients treated with nilotinib, two presented complete cytogenetic response, two major molecular response, and five loss of response to treatment. Of seven patients treated with dasatinib, two had complete cytogenetic response, two major molecular response, and four loss of response to treatment.
  
  
  CONCLUSIONS
  Of patients studied, 30 % was resistant to imatinib, 52 % achieved a complete cytogenetic response, and 42 % major molecular response. The use of second generation tyrosine kinase inhibitors led to obtain a complete cytogenetic and major molecular response in fewer time.
authors.affiliation: Servicio de Hematología, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México. arman2mil@hotmail.com.
authors.forename: Armando
authors.initials: A
authors.lastname: Ibarra-Hernández
authors.forename: Lluvia Sugey
authors.initials: LS
authors.lastname: Sosa-Quintero
authors.forename: Oscar Miguel
authors.initials: OM
authors.lastname: Garcés-Ruiz
authors.forename: Lilia Beatriz
authors.initials: LB
authors.lastname: Aguilar-López
authors.forename: Benjamín
authors.initials: B
authors.lastname: Rubio-Jurado
authors.forename: Arturo
authors.initials: A
authors.lastname: Vega-Ruiz
mesh_terms: D000328:Adult; D001549:Benzamides / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D000069439:Dasatinib; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib
keywords: Chronic myelogenous leukemia, BCR-ABL positive; Molecular mechanisms of pharmacological action; Protein-tyrosine kinases